Increased genetic diversity of ADME genes in African Americans compared with their putative ancestral source populations and implications for Pharmacogenomics

BMC Genetics

Shuhua Xu¹  Dongsheng Lu¹  Lei Tian¹  Chao Zhang¹  Xingzhen Lao²  Jing Li¹ 

[1] Max Planck Independent Research Group on Population Genomics, Chinese Academy of Sciences and Max Planck Society (CAS-MPG) Partner Institute for Computational Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China;School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China

关键词: Genetic admixture;    Genetic diversity;    Drug response heterogeneity;    African Americans;    ADME genes;   

Others  :  866519
DOI  :  10.1186/1471-2156-15-52

 received in 2013-10-24, accepted in 2014-04-24,  发布年份 2014

【 摘 要 】

Background

African Americans have been treated as a representative population for African ancestry for many purposes, including pharmacogenomic studies. However, the contribution of European ancestry is expected to result in considerable differences in the genetic architecture of African American individuals compared with an African genome. In particular, the genetic admixture influences the genomic diversity of drug metabolism-related genes, and may cause high heterogeneity of drug responses in admixed populations such as African Americans.

Results

The genomic ancestry information of African-American (ASW) samples was obtained from data of the 1000 Genomes Project, and local ancestral components were also extracted for 32 core genes and 252 extended genes, which are associated with drug absorption, distribution, metabolism, and excretion (ADME) genes. As expected, the global genetic diversity pattern in ASW was determined by the contributions of its putative ancestral source populations, and the whole profiles of ADME genes in ASW are much closer to those in YRI than in CEU. However, we observed much higher diversity in some functionally important ADME genes in ASW than either CEU or YRI, which could be a result of either genetic drift or natural selection, and we identified some signatures of the latter. We analyzed the clinically relevant polymorphic alleles and haplotypes, and found that 28 functional mutations (including 3 missense, 3 splice, and 22 regulator sites) exhibited significantly higher differentiation between the three populations.

Conclusions

Analysis of the genetic diversity of ADME genes showed differentiation between admixed population and its ancestral source populations. In particular, the different genetic diversity between ASW and YRI indicated that the ethnic differences in pharmacogenomic studies are broadly existed despite that African ancestry is dominant in Africans Americans. This study should advance our understanding of the genetic basis of the drug response heterogeneity between populations, especially in the case of population admixture, and have significant implications for evaluating potential inter-population heterogeneity in drug treatment effects.

【 授权许可】

   
2014 Li et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Shastry BS: Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J 2006, 6(1):16-21.
• [2]Haga SB, LaPointe NM: The potential impact of pharmacogenetic testing on medication adherence. Pharmacogenomics J 2013, 13(6):481-483.
• [3]Sim SC, Kacevska M, Ingelman-Sundberg M: Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J 2013, 13(1):1-11.
• [4]Guessous I, Gwinn M, Khoury MJ: Genome-wide association studies in pharmacogenomics: untapped potential for translation. Genome Med 2009, 1(4):46. BioMed Central Full Text
• [5]Ma Q, Lu AY: Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 2011, 63(2):437-459.
• [6]Eichelbaum M, Ingelman-Sundberg M, Evans WE: Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006, 57:119-137.
• [7]Rosenberg NA, Pritchard JK, Weber JL, Cann HM, Kidd KK, Zhivotovsky LA, Feldman MW: Genetic structure of human populations. Science 2002, 298(5602):2381-2385.
• [8]Rosenberg NA: A population-genetic perspective on the similarities and differences among worldwide human populations. Hum Biol 2011, 83(6):659-684.
• [9]Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmoller J, Halpert JR, Zanger UM, Wojnowski L: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetic 2001, 11(9):773-779.
• [10]Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A: Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genom 2009, 19(2):170-179.
• [11]Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R, Poloni ES: Worldwide distribution of NAT2 diversity: Implications for NAT2 evolutionary history. BMC Genet 2008, 9.
• [12]Dang MT, Hambleton J, Kayser SR: The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 2005, 39(6):1008-1012.
• [13]Phan VH, Moore MM, McLachlan AJ, Piquette-Miller M, Xu H, Clarke SJ: Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert opin Drug metab Toxicol 2009, 5(3):243-257.
• [14]Tishkoff SA, Reed FA, Friedlaender FR, Ehret C, Ranciaro A, Froment A, Hirbo JB, Awomoyi AA, Bodo JM, Doumbo O, Ibrahim M, Juma AT, Kotze MJ, Lema G, Moore JH, Mortensen H, Nyambo TB, Omar SA, Powell K, Pretorius GS, Smith MW, Thera MA, Wambebe C, Weber JL, Williams SM: The genetic structure and history of Africans and African Americans. Science 2009, 324(5930):1035-1044.
• [15]Pillai G, Davies G, Denti P, Steimer JL, McIlleron H, Zvada S, Chigutsa E, Ngaimisi E, Mirza F, Tadmor B, Holford NH: Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa. CPT pharmacometrics Syst pharmacol. 2013, 2:e69.
• [16]Jin W, Xu S, Wang H, Yu Y, Shen Y, Wu B, Jin L: Genome-wide detection of natural selection in African Americans pre- and post-admixture. Genome Res 2012, 22(3):519-527.
• [17]Zakharia F, Basu A, Absher D, Assimes TL, Go AS, Hlatky MA, Iribarren C, Knowles JW, Li J, Narasimhan B, Sidney S, Southwick A, Myers RM, Quertermous T, Risch N, Tang H: Characterizing the admixed African ancestry of African Americans. Genome Biol 2009, 10(12):R141. BioMed Central Full Text
• [18]Cornuet JM, Luikart G: Description and power analysis of two tests for detecting recent population bottlenecks from allele frequency data. Genetics 1996, 144(4):2001-2014.
• [19]Stumpf MP: Haplotype diversity and SNP frequency dependence in the description of genetic variation. Eur J Hum Genet 2004, 12(6):469-477.
• [20]Vijayan NN, Mathew A, Balan S, Natarajan C, Nair CM, Allencherry PM, Banerjee M: Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by ABCB1 genotypes: a study from a south Indian perspective. Pharmacogenomics 2012, 13(10):1119-1127.
• [21]Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, Hosoi Y, Takekita Y, Mandelli L, Azuma J, Kinoshita T: ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuro Biol Psychoph 2008, 32(2):398-404.
• [22]Leschziner GD, Andrew T, Pirmohamed M, Johnson MR: ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007, 7(3):154-179.
• [23]Soyama A, Saito Y, Hanioka N, Maekawa K, Komamura K, Kamakura S, Kitakaze M, Tomoike H, Ueno K, Goto Y, Kimura H, Katoh M, Sugai K, Saitoh O, Kawai M, Ohnuma T, Ohtsuki T, Suzuki C, Minami N, Kamatani N, Ozawa S, Sawada J: Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metabolism Pharmacokinet 2005, 20(1):24-33.
• [24]Lin KM, Tsou HH, Tsai IJ, Hsiao MC, Hsiao CF, Liu CY, Shen WW, Tang HS, Fang CK, Wu CS, Lu SC, Kuo HW, Liu SC, Chan HW, Hsu YT, Tian JN, Liu YL: CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine. Pharmacogenomics 2010, 11(11):1535-1543.
• [25]Popat RA, Van Den Eeden SK, Tanner CM, Kamel F, Umbach DM, Marder K, Mayeux R, Ritz B, Ross GW, Petrovitch H, Topol B, McGuire V, Costello S, Manthripragada AD, Southwick A, Myers RM, Nelson LM: Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease. Eur J Neurol 2011, 18(5):756-765.
• [26]Price AL, Tandon A, Patterson N, Barnes KC, Rafaels N, Ruczinski I, Beaty TH, Mathias R, Reich D, Myers S: Sensitive detection of chromosomal segments of distinct ancestry in admixed populations. PLoS Genetics 2009, 5(6):e1000519.
• [27]Ingman M, Kaessmann H, Paabo S, Gyllensten U: Mitochondrial genome variation and the origin of modern humans. Nature 2000, 408(6813):708-713.
• [28]Serre D, Paabo SP: Evidence for gradients of human genetic diversity within and among continents. Genome Res 2004, 14(9):1679-1685.
• [29]Smith MW, Patterson N, Lautenberger JA, Truelove AL, McDonald GJ, Waliszewska A, Kessing BD, Malasky MJ, Scafe C, Le E, De Jager PL, Mignault AA, Yi Z, De The G, Essex M, Sankale JL, Moore JH, Poku K, Phair JP, Goedert JJ, Vlahov D, Williams SM, Tishkoff SA, Winkler CA, De La Vega FM, Woodage T, Sninsky JJ, Hafler DA, Altshuler D, Gilbert DA, et al.: A high-density admixture map for disease gene discovery in african americans. Am J Hum Genet 2004, 74(5):1001-1013.
• [30]Pena SD: The fallacy of racial pharmacogenomics. Braz J Biol Res 2011, 44(4):268-275.
• [31]Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA, Genomes Project C, Abecasis GR: An integrated map of genetic variation from 1,092 human genomes. Nature 2012, 491(7422):56-65.
• [32]Browning BL, Browning SR: Rapid and accurate haplotype phasing and missing data inference for whole genome association studies using localized haplotype clustering. Genet Epidemiol 2007, 31(6):606-606.
• [33]Ke X, Taylor MS, Cardon LR: Singleton SNPs in the human genome and implications for genome-wide association studies. Eur J Hum Genet 2008, 16(4):506-515.
• [34]Li J, Zhang L, Zhou H, Stoneking M, Tang K: Global patterns of genetic diversity and signals of natural selection for human ADME genes. Hum Mol Genet 2011, 20(3):528-540.
• [35]Daly TM, Dumaual CM, Miao X, Farmen MW, Njau RK, Fu DJ, Bauer NL, Close S, Watanabe N, Bruckner C, Hardenbol P, Hockett RD: Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport. Clin Chem 2007, 53(7):1222-1230.
• [36]Pruitt KD, Tatusova T, Maglott DR: NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res 2007, 35(Database issue):D61-D65.
• [37]McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F: Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 2010, 26(16):2069-2070.
• [38]Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, Karczewski KJ, Park J, Hitz BC, Weng S, Cherry JM, Snyder M: Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 2012, 22(9):1790-1797.
• [39]Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE: Pharmacogenomics Knowledge for Personalized Medicine. Clin Pharmacol Ther 2012, 92(4):414-417.
• [40]Sankararaman S, Sridhar S, Kimmel G, Halperin E: Estimating local ancestry in admixed populations. Am J Hum Genet 2008, 82(2):290-303.
• [41]Maples BK, Gravel S, Kenny EE, Bustamante CD: RFMix: a discriminative modeling approach for rapid and robust local-ancestry inference. Am J Hum Genet 2013, 93(2):278-288.
• [42]Churchhouse C, Marchini J: Multiway admixture deconvolution using phased or unphased ancestral panels. Genet Epidemiol 2013, 37(1):1-12.
• [43]Thomas MG, Weale ME, Jones AL, Richards M, Smith A, Redhead N, Torroni A, Scozzari R, Gratrix F, Tarekegn A, Wilson JF, Capelli C, Bradman N, Goldstein DB: Founding mothers of Jewish communities: Geographically separated Jewish groups were independently founded by very few female ancestors. Am J Hum Genet 2002, 70(6):1411-1420.
• [44]Birnbaum ZW, Tingey FH: One-Sided Confidence Contours for Probability Distribution Functions. Ann Math Stat 1951, 22(4):592-596.
• [45]Weir BS, Cockerham CC: Estimating F-Statistics for the Analysis of Population-Structure. Evolution 1984, 38(6):1358-1370.
• [46]Shriver MD, Kennedy GC, Parra EJ, Lawson HA, Sonpar V, Huang J, Akey JM, Jones KW: The genomic distribution of population substructure in four populations using 8,525 autosomal SNPs. Hum Genomics 2004, 1(4):274-286. BioMed Central Full Text
• [47]Voight BF, Kudaravalli S, Wen XQ, Pritchard JK: A map of recent positive selection in the human genome. PloS Biol 2006, 4(4):659-659.
• [48]Nielsen R, Williamson S, Kim Y, Hubisz MJ, Clark AG, Bustamante C: Genomic scans for selective sweeps using SNP data. Genome Res 2005, 15(11):1566-1575.